C&EN Whitepaper
Critical API Attributes and the Major Impact They Can Have on Drug Product Development
Brought to you by Thermo Fisher Scientific
Small molecule drug substance development is often completed without consideration for the final drug product formulation. To some extent this is necessary, as drug substance must be generated before any product development activities can commence. However, both activities are intimately linked by the final purification and isolation step of the chemical synthesis and manufacturing process.

Read this whitepaper to discover why an alternative, integrated approach to formulation should be considered based on the impact of certain API properties on the final drug product.

Key Objectives:

  • Impact of API properties on formulation
  • Impact of particle size
  • The importance of an integrated drug development approach

Brought to you by:
Thermo Fisher Scientific
Thermo Fisher Scientific
Please complete the form to download the whitepaper.

*I can withdraw my consent and unsubscribe at any time by e-mailing reply@thermofisher.com . I acknowledge Thermo Fisher Scientific will process my Personal Information according to its Privacy Policy , which includes information about my rights. https://resource.thermofisher.com/page/DB_17_0119/?cid=fl-legalentities

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) via email, in accordance with the ACS Privacy Policy .

Copyright © 2024 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy